Literature DB >> 11157852

HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition.

B Riteau1, C Menier, I Khalil-Daher, S Martinozzi, M Pla, J Dausset, E D Carosella, N Rouas-Freiss.   

Abstract

It is now acknowledged that the pattern of HLA-G expression is not restricted to extravillous cytotrophoblast cells, as several studies described HLA-G in HLA class I+ cells, such as thymic epithelial cells, cytokine-activated monocytes and some tumors. In these situations, HLA-G may provide an additional inhibitory signal to escape from NK cell-mediated cytotoxicity. Accordingly, the aim of this study was to define the behavior of HLA-G once it is co-expressed into an HLA-A, -B, -C and -E+ cell line. For this purpose, HLA-G1 cDNA was transfected into an HLA class I+ melanoma cell line which was used as a target towards freshly isolated peripheral blood NK cells. Cytotoxic experiments using either anti-HLA-G1 or anti-HLA-G1 inhibitory receptor mAb show that HLA-G1 boosts the HLA class I-mediated inhibition of polyclonal NK cells through interaction with ILT-2, which appears as the major HLA-G1 inhibitory receptor involved. Nevertheless, HLA-G1 is also able to inhibit the cytolytic activity of an ILT-2- NK clone which otherwise expresses another HLA-G1 inhibitory receptor belonging to the KIR103 gene family. In order to more precisely define the relative role exerted by HLA-G1 versus -E on polyclonal NK cells, antibody-blocking assays were carried out using either anti-HLA class I or anti-CD94/NKG2A. Results demonstrate that in the absence of HLA-G1, the naturally expressed HLA class I-mediated NK inhibition is predominantly exerted by HLA-E through binding with CD94/NKG2A. In contrast, once HLA-G1 is expressed, it becomes the major NK inhibitory ligand.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11157852     DOI: 10.1093/intimm/13.2.193

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  39 in total

1.  Permanent silencing of NKG2A expression for cell-based therapeutics.

Authors:  Constança Figueiredo; Axel Seltsam; Rainer Blasczyk
Journal:  J Mol Med (Berl)       Date:  2008-11-11       Impact factor: 4.599

2.  In vitro evidence of the presence of mesenchymal stromal cells in cervical cancer and their role in protecting cancer cells from cytotoxic T cell activity.

Authors:  Juan J Montesinos; María de L Mora-García; Héctor Mayani; Eugenia Flores-Figueroa; Rosario García-Rocha; Guadalupe R Fajardo-Orduña; Marta E Castro-Manrreza; Benny Weiss-Steider; Alberto Monroy-García
Journal:  Stem Cells Dev       Date:  2013-06-14       Impact factor: 3.272

Review 3.  Are stem cells a potential therapeutic tool in coeliac disease?

Authors:  Rachele Ciccocioppo; Giuseppina Cristina Cangemi; Emanuela Anna Roselli; Peter Kruzliak
Journal:  Cell Mol Life Sci       Date:  2014-12-16       Impact factor: 9.261

4.  HLA-G expression in gastric carcinoma: clinicopathological correlations and prognostic impact.

Authors:  Giuseppe Murdaca; Paola Calamaro; Francesca Lantieri; Simona Pigozzi; Luca Mastracci; Federica Grillo; Ottavia Magnani; Paola Ceppa; Francesco Puppo; Roberto Fiocca
Journal:  Virchows Arch       Date:  2018-05-29       Impact factor: 4.064

Review 5.  Cutaneous squamous cell cancer (cSCC) risk and the human leukocyte antigen (HLA) system.

Authors:  Pooja Yesantharao; Wei Wang; Nilah M Ioannidis; Shadmehr Demehri; Alice S Whittemore; Maryam M Asgari
Journal:  Hum Immunol       Date:  2017-02-07       Impact factor: 2.850

Review 6.  HLA-G-mediated NK cell senescence promotes vascular remodeling: implications for reproduction.

Authors:  Sumati Rajagopalan
Journal:  Cell Mol Immunol       Date:  2014-07-07       Impact factor: 11.530

7.  Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy.

Authors:  Kei Ishibashi; Takumi Kumai; Takayuki Ohkuri; Akemi Kosaka; Toshihiro Nagato; Yui Hirata; Kenzo Ohara; Kensuke Oikawa; Naoko Aoki; Naoko Akiyama; Masatoshi Sado; Masahiro Kitada; Yasuaki Harabuchi; Esteban Celis; Hiroya Kobayashi
Journal:  Oncoimmunology       Date:  2016-03-30       Impact factor: 8.110

Review 8.  Switch from protective to adverse inflammation during influenza: viral determinants and hemostasis are caught as culprits.

Authors:  Fatma Berri; Vuong Ba Lê; Martine Jandrot-Perrus; Bruno Lina; Béatrice Riteau
Journal:  Cell Mol Life Sci       Date:  2013-10-04       Impact factor: 9.261

9.  Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G.

Authors:  Mitsunori Shiroishi; Kouhei Tsumoto; Kimie Amano; Yasuo Shirakihara; Marco Colonna; Veronique M Braud; David S J Allan; Azure Makadzange; Sarah Rowland-Jones; Benjamin Willcox; E Yvonne Jones; P Anton van der Merwe; Izumi Kumagai; Katsumi Maenaka
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-09       Impact factor: 11.205

10.  Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Mol Med       Date:  2015-08-24       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.